Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Respiratory Medicine

Journal Scan / Research · July 03, 2024

Benefit–Risk Profile of P2X3 Receptor Antagonists in the Treatment of Patients With Chronic Cough

Chest

 

Additional Info

Disclosure statements are available on the authors' profiles:

Chest
Benefit-risk profile of P2X3 receptor antagonists for treatment of chronic cough: Dose-response model-based network meta-analysis
Chest 2024 Jun 08;[EPub Ahead of Print], S Yamamoto, N Horita, J Hara, M Sasamoto, Y Kanemitsu, Y Hara, Y Obase, T Kaneko, A Niimi, H Mukae

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading